Omnicom Health Group, part of Omnicom Group Inc., became a Veeva Systems Global Content Partner. This expanded partnership will help the world’s largest healthcare marketing and communications group better support omnichannel experiences and content management initiatives for mutual customers.

Building on the success of its COVID-19 mRNA vaccine, Moderna, Inc. is partnering with the nonprofit scientific research organization IAVI to develop treatments and vaccines against global health threats.

Voyager Therapeutics partnered with Novartis in a potential $1.7 billion deal. The collaboration will enable Novartis to use the gene therapy company’s capsid discovery platform to create new treatments for three undisclosed CNS targets. 

The Centers for Disease Control and Prevention (CDC) awarded Palantir Technologies Inc. a $5.3 million contract to manage distribution of COVID-19 drugs in the United States, the software maker said on February 22.

BioNTech and Medigene announced a global agreement to develop T-cell immunotherapies against cancer. The three-year collaboration will focus on multiple solid tumor targets. 

In concert with partner Senseonics Holdings, Ascensia Diabetes Care announced that the U.S. Food and Drug Administration signed off on the Eversense E3 Continuous Glucose Monitoring System (CGM) System.

New York-based Ovid Therapeutics and Healx entered a strategic partnership to investigate the compound gaboxadol to treat Fragile X Syndrome (FXS).

Amgen posted a 3 percent rise in total 2021 fourth-quarter revenue to $6.8 billion and a 2 percent increase in total revenue for the year to $26 billion, driven mainly through wins from “other” gains. 

Medable Inc., the leading software provider for patient-centered clinical trials, launched the Medable Partner Network – uniting a diverse ecosystem of technology, service, data, site, and direct-to-patient partners that work together to accelerate deployment of decentralized clinical trials.

Seagen shared that the company’s Phase III trial of Adcetris (brentuximab vedotin) demonstrated significant improvements in the overall survival of patients diagnosed with advanced classical Hodgkin lymphoma.